Alternative inactivated poliovirus vaccines adjuvanted with Quillaja brasiliensis or Quil-A saponins are equally effective in inducing specific immune responses

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  De Costa, Fernanda ^a   Yendo, Anna Carolina A ^a   Cibulski, Samuel P ^a,b   Fleck, Juliane D ^c   Roehe, Paulo M ^a,b   Spilki, Fernando R ^c   Gosmann, Grace ^a   Fett Neto, Arthur G ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Faculty of Pharmacy UFRGS ^*  (Brazil)

^c UNIVERSIDADE FEEVALE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; MESSENGER RNA; POLIOMYELITIS VACCINE; QB 90; QUIL A; QUILLAJA SAPONIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOGLOBULIN A; SAPONIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MIXTURE; FECES LEVEL; FEMALE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PLANT LEAF; QUILLAJA; QUILLAJA BRASILIENSIS; SPLEEN CELL; VAGINAL LAVAGE; ANIMAL; CHEMISTRY; DELAYED HYPERSENSITIVITY; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; POLIOMYELITIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HYPERSENSITIVITY, DELAYED; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; QUILLAJA; SAPONINS;

EID: 84929046241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105374     Document Type: Article

References (29)

1. Mangal TD, Aylward RB, Grassly NC (2013) The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting. Am J Epidemiol 178: 1579-1587.
2. Grassly NC (2013) The final stages of the global eradication of poliomyelitis. Philos T R Soc B 368: 1-14.
3. Bhutta ZA (2013) Conflict and polio: Winning the polio wars. JAMA 310: 905-906.
4. Heinsbroek E, Ruitenberg EJ (2010) The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 28: 3778-3783.
5. Steil BP, Jorquera P, Westdijk J, Bakker WAM, Johnston RE, et al. (2014) A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 32: 558-563.
6. Hawken J, Troy SB (2012) Adjuvants and inactivated polio vaccine: a systematic review. Vaccine 30: 6971-6719.
7. Reitz R (1996) Flora Ilustrada Catarinense - Rosáceas. Itajaí: Herbário Barbosa Rodrigues. 135 p.
8. Kauffmann C, Machado AM, Fleck JD, Provensi G, Pires VS, et al. (2004) Constituents from leaves of Quillaja brasiliensis. Nat Prod Res 18: 153-157. (Pubitemid 38213213)
9. Fleck JD, Kauffmann C, Spilki F, Lencina CL, Roehe PM, et al. (2006) Adjuvant activity of Quillaja brasiliensis saponins on the immune responses to bovine herpesvirus type 1 in mice. Vaccine 24: 7129-7134. (Pubitemid 46107199)
10. Silveira F, Cibulski SP, Varela AP, Marqués JM, Chabalgoity A, et al. (2011) Quillaja brasiliensis saponins are less toxic than Quil A and have similar properties when used as an adjuvant for a viral antigen preparation. Vaccine 29: 9177-9182.
11. Sun H-X, Xie Y, Ye Y-P (2009) Advances in saponin-based adjuvants. Vaccine 27: 1787-1796.
12. Mastelic B, Ahmed S, Egan WM, Del Giudice G, Golding H, et al. (2010) Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 38: 594-601.
13. de Costa F, Yendo AC, Fleck JD, Gosmann G, Fett-Neto AG (2011) Immunoadjuvant and anti-inflammatory plant saponins: characteristics and biotechnological approaches towards sustainable production. Mini Rev Med Chem 11: 857-880.
14. Martín R, Briones R (1999) Industrial uses and sustainable supply of Quillaja saponaria (Rosaceae) saponins. Econ Bot 53: 302-311. (Pubitemid 29452289)
15. Fleck JD, Schwambach J, Almeida ME, Yendo ACA, Costa F, et al. (2009) Immunoadjuvant saponin production in seedlings and micropropagated plants of Quillaja brasiliensis. In Vitro Cell Dev-Pl 45: 715-720.
16. de Costa F, Yendo ACA, Fleck JD, Gosmann G, Fett-Neto AG (2013) Accumulation of a bioactive triterpene saponin fraction of Quillaja brasiliensis leaves is associated with abiotic and biotic stresses. Plant Physiol Bioch 66: 56-62.
17. Freshney RI (2010) Subculture and Cell Lines. Culture of Animal Cells: John Wiley & Sons, Inc. pp. 187-206.
18. Salk JE, Gori JB (1960) A review of theoretical, experimental, and practical considerations in the use of formaldehyde for the inactivation of poliovirus. Ann NY Acad Sci 83: 609-637.
19. Spilki FR, Esteves PA, da Silva AD, Franco AC, Rijsewijk FA, et al. (2005) A monoclonal antibody-based ELISA allows discrimination between responses induced by bovine herpesvirus subtypes 1 (BoHV-1.1) and 2 (BoHV-1.2). J Virol Methods 129: 191-193. (Pubitemid 41338575)
20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
21. Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138-146. (Pubitemid 26074503)
22. Broere F, Apasov S, Sitkovsky M, Eden W (2011) A2 T cell subsets and T cell-mediated immunity. In: Nijkamp FP, Parnham MJ, editors. Principles of Immunopharmacology: Birkhäuser Basel. pp. 15-27.
23. Hernández A, Yager JA, Wilkie BN, Leslie KE, Mallard BA (2005) Evaluation of bovine cutaneous delayed-type hypersensitivity (DTH) to various test antigens and a mitogen using several adjuvants. Vet Immunol Immunop 104: 45-58. (Pubitemid 40127440)
24. Buisman AM, Sonsma JA, Kimman TG, Koopmans MP (2000) Mucosal and systemic immunity against poliovirus in mice transgenic for the poliovirus receptor: the poliovirus receptor is necessary for a virus-specific mucosal IgA response. J Infect Dis 181: 815-823. (Pubitemid 30194460)
25. Elson CO, Ealding W (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132: 2736-2741. (Pubitemid 14105650)
26. Yoshino N, Fujihashi K, Hagiwara Y, Kanno H, Takahashi K, et al. (2009) Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy. Vaccine 27: 4808-4817.
27. Sasaki S, Sumino K, Hamajima K, Fukushima J, Ishii N, et al. (1998) Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J Virol 72: 4931-4939. (Pubitemid 28215672)
28. Boyaka PN, Marinaro M, Jackson RJ, van Ginkel FW, Cormet-Boyaka E, et al. (2001) Oral QS-21 requires early IL-4 help for induction of mucosal and systemic immunity. J Immunol 166: 2283-2290. (Pubitemid 32173459)
29. Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V (2013) Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies. Int J Pharm 441: 636-642. Development